Document is current
Any future updates will be listed below
-
Authors
Kudrow, David
Hutchinson, Susan https://orcid.org/0000-0001-6353-2846
Pixton, Glenn C.
Fullerton, Terence
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03266588 at ClinicalTrials.govDocuments that mention this clinical trial
Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study
https://doi.org/10.1007/s40122-024-00675-6
Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study
https://doi.org/10.1007/s40122-024-00626-1
Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
https://doi.org/10.1007/s12325-021-01897-2
159 Long-term safety and discontinuation for rimegepant versus triptans: a matching-adjusted indirect comparison
https://doi.org/10.1136/jnnp-2025-abn.159
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 23 August 2024
Accepted: 14 October 2024
First Online: 9 November 2024
Declarations
:
: The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article. David Kudrow reports research grants from Pfizer, Lilly, Aeon, AbbVie, and Biohaven; speakers bureau for AbbVie; and serving on advisory boards for Lundbeck and AbbVie. Susan Hutchinson has served as a consultant for AbbVie, Astellas, Biohaven, Impel, Lilly, Lundbeck Teva, Theranica, and Upsher-Smith. She is on the speakers bureau for AbbVie, Astellas, Impel, Lilly, and Lundbeck. Glenn C. Pixton is an employee of Pfizer and owns stock/stock options in Pfizer, and owns stock in AbbVie. Terence Fullerton is an employee of Pfizer and owns stock/stock options in Pfizer.
: The study was conducted in accordance with Good Clinical Practice, as defined by the International Conference on Harmonisation, Good Laboratory Practice, the Declaration of Helsinki, and all applicable regulations. Prior to the study, all participants provided written informed consent, and the protocol received Institutional Review Board approval (Advarra IRB [IRB00000971], Schulman Associates IRB [IRB00007642; acquired by Advarra], and Biomedical Research Alliance New York [BRANY] IRB [IRB00000080]).
